CN Patent

CN115916822A — 使用抗CD79b免疫缀合物的方法

Assigned to Genentech Inc · Expires 2023-04-04 · 3y expired

What this patent protects

本文提供了使用包含抗CD79b抗体的免疫缀合物与Bcl‑2抑制剂(诸如维奈托克)和抗CD20抗体(诸如奥滨尤妥珠单抗或利妥昔单抗)组合以治疗B细胞增生性疾病(诸如滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤)的方法。

USPTO Abstract

本文提供了使用包含抗CD79b抗体的免疫缀合物与Bcl‑2抑制剂(诸如维奈托克)和抗CD20抗体(诸如奥滨尤妥珠单抗或利妥昔单抗)组合以治疗B细胞增生性疾病(诸如滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN115916822A
Jurisdiction
CN
Classification
—
Expires
2023-04-04
Drug substance claim
No
Drug product claim
No
Assignee
Genentech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.